GKOS
Glaukos Corporation
NYSE · USHealthcareMedical - Devices
$155.46-0.87%
Price as of Jul 20, 2026
GKOS growth
Glaukos Corporation growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +36.3%
- EBITDA
- -89.6%
- EBIT
- +17.4%
- EPS
- -38.4%
- Free cash flow
- +65.3%
- Operating cash flow
- +80.9%
Forward estimates
- Revenue
- +25.1%
- EBITDA
- +5.7%
- EPS
- +101.8%
Three-year CAGR
- Revenue
- +21.5%
- EBITDA
- -52.7%
- EBIT
- +29.1%
- Net income
- -28.2%
- EPS
- -18.4%
- Free cash flow
- +20.1%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.